ClinicalTrials.gg
Not yet recruitingNCT07622394CORE-CTRCDUpdated Jun 3, 2026

Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors

An interventional study of Structured Cardio-Oncology Rehabilitation and Usual Care in Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology and Cancer Survivorship, sponsored by Xinjiang Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Xinjiang Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
46th of 247
800 · median 130
Started
2026
with 42 others
No phase
115 of 377
51 open now
Primary completion
2029-09
later than 159 of 181 live
Registered
353rd of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 46th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2026, is one of 115 with no phase, reaches primary completion later than 159 of the 181 other live ones, and was the 353rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management, high-quality randomized controlled evidence regarding its efficacy in cardio-oncology populations remains limited.

This multicenter, prospective, parallel-group, superiority randomized controlled trial aims to evaluate whether a structured cardio-oncology rehabilitation (CORE) program combined with usual care can improve cardiovascular outcomes in patients with CTRCD or cancer survivors at high cardiovascular risk, compared with usual care alone.

A total of 800 participants will be randomized in a 1:1 ratio to receive either structured cardio-oncology rehabilitation plus usual care or usual care alone. The intervention includes individualized exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. Participants will be followed for 12 months.

The primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months. Secondary endpoints include changes in cardiorespiratory fitness, cardiac function, biomarkers, quality of life, physical function, psychological status, safety outcomes, and health economic outcomes.

Read the detailed description

With advances in anti-cancer therapies, the number of cancer survivors has increased substantially worldwide. However, cancer therapy-related cardiac dysfunction (CTRCD) has emerged as a major long-term complication associated with increased cardiovascular morbidity, mortality, reduced quality of life, and impaired survival. Current management strategies primarily focus on pharmacologic prevention and treatment, while evidence-based non-pharmacologic interventions capable of improving hard cardiovascular outcomes remain insufficient.

Cardiac rehabilitation is a Class I recommended intervention for patients with cardiovascular diseases and has demonstrated benefits in improving cardiorespiratory fitness, reducing cardiovascular events, and enhancing quality of life. Emerging studies suggest that cardio-oncology rehabilitation may improve exercise capacity and cardiac function in cancer survivors; however, most existing studies are limited by small sample size, single-center design, and lack of hard clinical endpoints.

This study is a multicenter, prospective, parallel-group, superiority randomized controlled trial designed to evaluate the efficacy and safety of a structured cardio-oncology rehabilitation (CORE) program in patients with CTRCD or cancer survivors at high cardiovascular risk.

A total of 800 participants will be enrolled and randomized in a 1:1 ratio to either:

  1. Structured cardio-oncology rehabilitation plus usual care; or
  2. Usual care alone.

The intervention consists of a 12-week intensive rehabilitation phase followed by long-term maintenance guidance. Core components include:

  • Individualized aerobic and resistance exercise training;
  • Nutritional assessment and management;
  • Psychosocial and behavioral support;
  • Intensive cardiovascular risk-factor management;
  • Patient education and self-management support. The primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months, including cardiovascular death, myocardial infarction, ischemic stroke, hospitalization for worsening heart failure, or urgent ICD/CRT implantation due to malignant arrhythmia or heart failure.

Secondary endpoints include:

  • Changes in peak oxygen uptake (VO2peak);
  • Changes in left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS);
  • Biomarkers including hs-cTnI and NT-proBNP;
  • Quality-of-life assessments;
  • Physical function measures;
  • Psychological outcomes;
  • Safety outcomes and health economic outcomes. Outcome assessment personnel, laboratory staff, endpoint adjudicators, and statisticians will remain blinded to treatment allocation. The study includes centralized imaging review, standardized intervention protocols, electronic data capture, and oversight by an independent Data and Safety Monitoring Board (DSMB).

The findings of this trial are expected to provide high-quality evidence supporting the implementation of standardized cardio-oncology rehabilitation strategies in cancer survivors with cardiovascular toxicity or elevated cardiovascular risk.

03

Conditions studied

  • Cancer Therapy-Related Cardiac Dysfunction
  • Cardio-oncology
  • Cancer Survivorship
  • Cardiovascular Risk
  • Heart Failure

Browse trials for

Keywords

  • Structured Cardio-Oncology Rehabilitation
  • Cardiac Rehabilitation
  • Cancer Survivors
  • Major Adverse Cardiovascular Events
  • Exercise Training
  • Cardiorespiratory Fitness
  • CTRCD
04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older, regardless of sex.
  • or cytologically confirmed solid tumor or hematologic .
  • Completed curative anti-cancer therapy, or receiving stable adjuvant, maintenance, or palliative anti-cancer therapy.
  • Meets at least one criterion for cancer therapy-related cardiac dysfunction (CTRCD) or high cardiovascular risk, including reduced after anti-cancer therapy, high-dose anthracycline exposure, chest radiotherapy with cardiovascular risk factors, heart failure after anti-cancer therapy, or elevated cardiac injury/heart failure biomarkers.
  • Estimated of at least 24 months as assessed by the treating oncologist.
  • Able to complete baseline cardiopulmonary exercise testing and has no absolute to exercise training.
  • Able and willing to provide written and comply with study intervention and follow-up.

Exclusion criteria

Exclusion Criteria:

  • Active progressive requiring urgent anti-cancer therapy, or estimated less than 24 months.
  • Severe structural heart disease, including severe valvular disease, congenital heart disease, end-stage heart failure, or waiting for heart transplantation or left ventricular assist device implantation.
  • Absolute to exercise training, including uncontrolled malignant arrhythmia, acute myocarditis or pericarditis, acute coronary syndrome within 2 weeks, severe anemia, severe thrombocytopenia or neutropenia, uncontrolled hypertension, active infection, or severe musculoskeletal disease preventing exercise training.
  • Participation in a structured cardiac rehabilitation program within the previous 12 months, or regular moderate-to-vigorous aerobic or resistance training for at least 3 months before enrollment.
  • Implanted ICD or CRT, except pacemakers with exercise mode.
  • Severe psychiatric disease or cognitive impairment preventing participation.
  • Concurrent participation in another interventional clinical trial, or planned participation in another interventional clinical trial during the study period.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Structured Cardio-Oncology Rehabilitation

    Participants will receive a structured cardio-oncology rehabilitation program combined with usual care. The intervention includes individualized aerobic and resistance exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education for 12 weeks, followed by maintenance rehabilitation guidance through 12 months.

    Behavioral: Structured Cardio-Oncology Rehabilitation

  • Active comparator
    Usual Care

    Participants will receive usual cardio-oncology care, including routine oncology and cardiovascular follow-up and general health advice, without structured cardio-oncology rehabilitation.

    Behavioral: Usual Care

Interventions

  • BehavioralStructured Cardio-Oncology Rehabilitation

    A structured cardio-oncology rehabilitation program including individualized aerobic and resistance exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. The intervention consists of a 12-week intensive rehabilitation phase followed by maintenance rehabilitation guidance through 12 months.

  • BehavioralUsual Care

    Participants receive routine oncology and cardiovascular follow-up and general health advice without structured cardio-oncology rehabilitation or supervised exercise training.

06

What researchers measure

Primary outcomes

  1. Time to First Major Adverse Cardiovascular Event (MACE)

    Time from randomization to the first occurrence of a major adverse cardiovascular event (MACE), including cardiovascular death, myocardial infarction, ischemic stroke, hospitalization for worsening heart failure, or urgent ICD/CRT implantation due to malignant arrhythmia or heart failure.

    Time frame: From randomization to 12 months

Secondary outcomes

  1. Change in Peak Oxygen Uptake

    Change in peak oxygen uptake (VO2peak) measured by cardiopulmonary exercise testing.

    Time frame: From baseline to 12 months

  2. Change in HADS Depression Score

    The Hospital Anxiety and Depression Scale (HADS) Depression subscale ranges from 0 to 21, with higher scores indicating greater depressive symptoms.

    Time frame: From baseline to 12 months

  3. Change in Left Ventricular Ejection Fraction

    Change in left ventricular ejection fraction (LVEF) measured by three-dimensional echocardiography.

    Time frame: From baseline to 12 months

  4. Change in Global Longitudinal Strain

    Change in global longitudinal strain (GLS) measured by echocardiography.

    Time frame: From baseline to 12 months

  5. Change in NT-proBNP

    Change in N-terminal pro-B-type natriuretic peptide level.

    Time frame: From baseline to 12 months

  6. Exercise-Related Adverse Events

    Incidence of adverse events related to the rehabilitation intervention or exercise training.

    Time frame: From randomization to 12 months

  7. Change in High-Sensitivity Cardiac Troponin I

    Change in high-sensitivity cardiac troponin I level.

    Time frame: From baseline to 12 months

  8. Change in 6-Minute Walk Distance

    Change in 6-minute walk distance measured by the 6-minute walk test.

    Time frame: From baseline to 12 months

  9. Change in SF-36 Score

    Change in the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) score. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: From baseline to 12 months

  10. Change in EORTC QLQ-C30 Global Health Status Score

    Change in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status score. Scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: From baseline to 12 months

  11. Change in Hospital Anxiety and Depression Scale (HADS) Anxiety subscale score.

    The Hospital Anxiety and Depression Scale (HADS) Anxiety subscale ranges from 0 to 21, with higher scores indicating greater anxiety symptoms.

    Time frame: From baseline to 12 months

  12. Anti-Cancer Treatment Interruption

    Incidence of interruption of anti-cancer treatment during the study period.

    Time frame: From randomization to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications arising from this study will be shared, including demographic data, baseline characteristics, outcome measures, adverse events, and follow-up data.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Beginning 12 months after publication of the primary study results and ending 5 years after publication.

Access criteria: Qualified researchers who provide a methodologically sound proposal may gain access to de-identified individual participant data and supporting documents. Requests will be reviewed by the study investigators and sponsoring institution. Data will be shared after approval of a data access agreement and will be provided through a secure data-sharing platform or institutional repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
Jun 3, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07622394
Lead sponsor
Xinjiang Medical University
Responsible party
Xiang Xie (Principal Investigator, Xinjiang Medical University) — Principal investigator
First posted
Jun 3, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Xiang Xie, PhD
Contact
xiangxie999@sina.com
+86 15099169036

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion